• In April 2026, Humana Inc. reported first-quarter 2026 results showing revenue of US$39,648 million, net income of US$1,186 million, diluted EPS of US$9.83, and announced completion of a US$276.13 million share repurchase program covering 1% of its shares.
• On the same day, Humana lowered its full-year 2026 GAAP diluted EPS guidance to at least US$8.36, signaling that profitability expectations have softened even as top-line growth continues.
• Next, we’ll examine how Humana’s reduced 2026 earnings guidance reshapes its existing investment narrative built around Medicare Advantage margin recovery.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Humana Investment Narrative Recap

To own Humana today, you need to believe in its core Medicare Advantage and CenterWell platform while accepting that earnings may be bumpy. The Q1 2026 beat on revenue but cut to full year GAAP EPS guidance to at least US$8.36 keeps the near term focus squarely on margin recovery, while the biggest risk remains how reimbursement, coding changes, and Stars outcomes feed through to medical costs and profitability. The guidance change appears material for near term expectations.

The most relevant recent move alongside earnings was Humana’s completion of its US$276.13 million buyback, retiring about 1% of shares. In the context of lower EPS guidance and past one off losses, this looks like a relatively modest use of capital that now sits alongside a steady US$0.885 quarterly dividend. For investors tracking catalysts, it underscores that management is keeping capital returns measured while it works through Medicare Advantage margin and regulatory uncertainties.

Yet alongside the margin reset, investors should also be aware of how MACRA’s V28 coding changes could affect high acuity members and...

Humana's narrative projects $184.2 billion revenue and $3.1 billion earnings by 2029.

Uncover how Humana's forecasts yield a $210.46 fair value, a 10% downside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were only assuming revenue near US$129.7 billion and earnings of about US$2.4 billion by 2028, so this latest guidance cut may push their already cautious Medicare Advantage margin concerns even further and is a reminder that your view on Humana can differ sharply from theirs.

Explore 9 other fair value estimates on Humana - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Humana research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.

No Opportunity In Humana?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.